TAT-CBD3A6K peptide

TAT-CBD3A6K peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-YGRKKRRQRRRARSRLKELRGVPRGL-OH

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-Arg-Ser-Arg-Leu-Lys-Glu-Leu-Arg-Gly-Val-Pro-Arg-Gly-Leu-OH

26

95.29%

C₁₃₇H₂₅₀N₆₀O₃₂

3249.82

Synthetic

Powder

TAT-CBD3A6K is an optimised variation of CBD3, the 15-amino acid peptide derived from the axonal collapsin response mediator protein 2 (CRMP-2), which is a modulator of N-type voltage-gated calcium channels (CaV2.2), conjugated to the cell penetrating motif of the HIV transduction domain protein TAT. TAT-CBD3A6K binds with greater affinity to Ca2+ channels and is more stable and less prone to unfolding than the parent peptide. TAT-CBD3A6K is anti-nociceptive in a rodent model of AIDS therapy-induced peripheral neuropathy

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Piekarz et al (2012) CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol. Pain 8 54 PMID: 22828369

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.